menu
    • menu
    [{"orgOrder":0,"company":"I-Mab Biopharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2021","type":"Inapplicable","leadProduct":"Plonmarlimab","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Pharmacology\/Toxicology","graph2":"Phase II\/ Phase III","graph3":"I-Mab Biopharma","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"I-Mab Biopharma \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"I-Mab Biopharma \/ Undisclosed"},{"orgOrder":0,"company":"Instituto Bioclon","sponsor":"Centre Antipoison et de Pharmacovigilance du Maroc | Institut Pasteur du Maroc","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"MEXICO","productType":"Cytotoxic Drug","year":"2011","type":"Inapplicable","leadProduct":"Alacramyn","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II\/ Phase III","graph3":"Instituto Bioclon","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto Bioclon \/ Centre Antipoison et de Pharmacovigilance du Maroc | Institut Pasteur du Maroc","highestDevelopmentStatusID":"9","companyTruncated":"Instituto Bioclon \/ Centre Antipoison et de Pharmacovigilance du Maroc | Institut Pasteur du Maroc"},{"orgOrder":0,"company":"EmeraMed","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Pharmacology\/Toxicology","country":"IRELAND","productType":"Undisclosed","year":"2019","type":"Inapplicable","leadProduct":"N1, N3-bis(2- mercaptoethyl)isophthalamide","moa":"Undisclosed","graph1":"Pharmacology\/Toxicology","graph2":"Phase II\/ Phase III","graph3":"EmeraMed","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Toxicology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"EmeraMed \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"EmeraMed \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            I-Mab Biopharma

                            China arrow
                            COMPAMED
                            Not Confirmed

                            I-Mab Biopharma

                            China arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Plonmarlimab

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab for Severe CO...

                            Details : The study aimed to determine the safety, efficacy and effects on cytokine levels following a single dose of 6 mg/kg of plonmarlimab or placebo in patients with severe COVID-19.

                            Product Name : Undisclosed

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 11, 2021

                            Lead Product(s) : Plonmarlimab

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EmeraMed

                            Ireland arrow
                            COMPAMED
                            Not Confirmed

                            EmeraMed

                            Ireland arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : N1, N3-bis(2- mercaptoethyl)isophthalamide

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            NBMI Treatment in Patients With Mercury Toxicity

                            Details : N1, N3-bis(2- mercaptoethyl)isophthalamide is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Mercury Poisoning.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            December 03, 2019

                            Lead Product(s) : N1, N3-bis(2- mercaptoethyl)isophthalamide

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Instituto Bioclon

                            Country arrow
                            COMPAMED
                            Not Confirmed

                            Instituto Bioclon

                            Country arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Alacramyn

                            Therapeutic Area : Pharmacology/Toxicology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Centre Antipoison et de Pharmacovigilance du Maroc | Institut Pasteur du Maroc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Trial of Equine F (ab')2 Antivenom for Treatment of Scorpion Envenomation in Morocco

                            Details : Alacramyn is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Scorpion Venoms.

                            Product Name : Undisclosed

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            April 18, 2011

                            Lead Product(s) : Alacramyn

                            Therapeutic Area : Pharmacology/Toxicology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Centre Antipoison et de Pharmacovigilance du Maroc | Institut Pasteur du Maroc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth